Nasopharyngeal carcinoma (NPC) is a non-lymphomatous, squamous-cell carcinoma that occurs in the epithelial lining of the nasopharynx. Despite improvements in more precise imaging, radiotherapy techniques ([@bib11]; [@bib17]) and chemotherapy ([@bib2]; [@bib16]), the survival rates of patients with advanced NPC remain poor. Identification of novel prognostic factors to recognise patients at high risk is warranted. Recently, the associations between ABO blood group and survival have been evaluated in pancreatic cancer ([@bib7]; [@bib18]), locoregional renal cell carcinoma ([@bib9]), triple-negative breast cancer ([@bib24]) or breast cancer ([@bib21]; [@bib8]), oesophageal squamous cell carcinoma ([@bib15]), and laryngeal squamous cell carcinoma ([@bib1]).

However, NPC has a distinct epidemiology, aetiology ([@bib3]) and clinical manifestation ([@bib23]) compared with other cancers, including other types of head and neck cancers. It remains unknown whether the ABO blood groups are associated with survival of NPC patients; therefore, we performed this study to elucidate the effect of ABO blood groups on the clinicopathologic features of NPC and to determine whether certain blood type is an independent predictor of prognosis.

Materials and methods
=====================

Patients
--------

The study was reviewed and approved by the Human Ethics Approval Committee at Sun Yat-sen University Cancer Center. After reviewing medical records, the first cohort included 924 from 986 patients of WHO histological type III ([@bib19]) treated with intensity-modulated radiotherapy (IMRT) between January 2003 and December 2009, while the second cohort included 1193 from 1406 patients of WHO histological type III treated with conventional radiotherapy (CRT) between January 2005 and December 2006 (the inclusion criteria were presented in [Supplementary Information](#sup1){ref-type="supplementary-material"}). We collected data on basic characteristics including age, gender, cigarette smoking status at diagnosis, alcohol drinking status at diagnosis, pre-treatment titre of serum immunoglobulin A against Epstein--Barr virus viral capsid antigen (VCA-IgA), and ABO blood type. Patients with missing data were excluded from this study. All patients were restaged by the seventh edition of AJCC/UICC Staging System for NPC ([@bib6]).

All patients were treated by IMRT or CRT with or without chemotherapy; the radiation techniques and chemotherapy regimens have been described previously ([@bib14]; [@bib12]; [@bib4]). The follow-up duration was calculated from the first day of therapy to either the day of death or the day of last examination.

Statistical analysis
--------------------

The following end points (interval to the first defining event) were estimated: overall survival (OS), locoregional relapse-free survival (LRFS), and distant metastasis-free survival (DMFS). All were examined using Kaplan--Meier methods and compared using log-rank test ([@bib10]). Multivariate analyses were performed using Cox proportional hazards model ([@bib5]). Two-sided *P-*values \<0.05 were considered significant. All tests were conducted using SPSS 16.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Baseline characteristics
------------------------

Basic characteristics of patients in each cohort are compared in terms of blood type A and non-A (B, AB, and O; [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). The proportions of blood types O, A, B, and AB were approximately similar to those of the cases in the recent case--control study ([@bib20]): 41.1%, 27.1%, 24.9%, and 6.9% in the IMRT cohort, and 39.8%, 27.1%, 26.7%, and 6.4% in the CRT cohort, respectively. There were no differences in the distributions of basic characteristics between blood type A and non-A in both cohorts (*P*⩾ 0.067).

Within a median follow-up duration of 68.0 months (range, 2.0--123.8 months) for the entire population, 8.3% (175 out of 2117) patients developed locoregional relapse, 12.5% (265 out of 2117) developed distant metastases, and 17.6% (373 out of 2117) died. The 3- and 5-year survival rates for the entire population were as follows: OS, 90.7% and 83.9% LRFS, 94.2% and 91.3% DMFS, 89.6% and 87.1%.

Effect of ABO blood groups on survival in the IMRT cohort
---------------------------------------------------------

Compared with patients with blood type O, the hazard ratios (HRs) in univariate analysis among patients with blood type A were 1.54 (95% CI 1.01--2.35; *P*=0.045) for OS, 1.10 (95% CI 0.59--2.05; *P*=0.756) for LRFS, and 1.38 (95% CI 0.89--2.14; *P*=0.146) for DMFS. Significant differences in OS and DMFS between patients with blood type A and blood type O were observed in multivariate analyses; the adjusted HRs for OS, LRFS, and DMFS were 1.58 (95% CI 1.03--2.43; *P*=0.035), 1.16 (95% CI 0.62--2.17; *P*=0.638), and 1.62 (95% CI 1.04--2.52; *P*=0.033), respectively, after accounting for age (⩽30, 31--40, 41--50, 51--60, and ⩾61 years-old), gender, smoking status, drinking status, T-stage, N-stage, VCA-IgA titer and chemotherapy. However, no significant differences in OS, LRFS, or DMFS were observed for patients with blood type B or AB in univariate or multivariate analysis when compared with patients with blood type O ([Table 1](#tbl1){ref-type="table"}).

We next examined the effect of ABO blood groups in terms of type A and non-A types. Blood type A was not significantly associated with LRFS; however, patients with type A had a significant lower OS and DMFS than those with non-A types (HR=1.45, 95% CI 1.00--2.10, *P*=0.048 for OS; HR=1.52, 95% CI 1.02--2.25, *P*=0.039 for DMFS; respectively) in univariate analysis ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}; [Table 1](#tbl1){ref-type="table"}). In addition, the higher risks of death and distant metastasis for patients with type A *vs* non-A types remained significant in multivariate analyses (HR=1.49, 95% CI 1.03--2.17, *P*=0.036 for OS; HR=1.68, 95% CI 1.13--2.51, *P*=0.011 for DMFS, respectively); no significant differences in LRFS were observed (adjusted HR=1.10, 95% CI 0.63--1.93; *P*=0.746; [Table 1](#tbl1){ref-type="table"}).

Effect of ABO blood groups on survival in the CRT cohort
--------------------------------------------------------

In this cohort, compared with patients with blood type O, patients with type A had significant lower OS and DMFS with HR of 1.46 (95% CI 1.07--1.98; *P*=0.017) and 1.73 (95% CI 1.18--2.53; *P*=0.005), respectively, in univariate analysis ([Table 2](#tbl2){ref-type="table"}); similar trends were not observed in the IMRT cohort. Differences in OS and DMFS between patients with type A and type O remained significant in multivariate analyses ([Table 2](#tbl2){ref-type="table"}). In addition, the effect of ABO blood groups, in terms of blood type A and non-A types in the CRT cohort was similar to results of the IMRT cohort ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}; [Table 2](#tbl2){ref-type="table"}).

Subgroup analyses
-----------------

The above results showed that the radiation technique barely affected the effect of blood group on survival in NPC. We therefore merged the IMRT and CRT cohort to further assess the association between ABO blood groups and OS in subgroups stratified by other prognoses. As shown in [Table 3](#tbl3){ref-type="table"}, the increased risk of death conferred by blood type A was not significantly modified by age (categorical), smoking status, drinking status, VCA-IgA titre, or type of chemotherapy. However, the increased risk of death conferred by blood type A was not observed among female patients (adjusted HR=1.18, 95% CI 0.70--1.98; *P*=0.531), patients with early stage disease (adjusted HR=1.56, 95% CI 0.85--2.85; *P*=0.150), or patients treated with radiotherapy alone (adjusted HR=0.74, 95% CI 0.41--1.35; *P*=0.332).

Discussion
==========

Previous studies have evaluated the association of ABO blood groups with the aetiology of NPC ([@bib22]; [@bib20]). However, no studies have examined its effect on survival of patients with established NPC. This is the first investigation to demonstrate that ABO blood groups are associated with patient survival in NPC, as patients with type A had independent, significantly lower OS and DMFS.

Our findings are quite similar to previous studies in pancreatic cancer ([@bib7]; [@bib18]), renal cell carcinoma ([@bib9]), and breast cancer ([@bib21]). As the first report, there are few existing comparable studies in NPC, or even other types of head and neck cancer. A study ([@bib1]) indicated no association between blood type and 5-year survival and mortality in laryngeal cancer, but these results are inconclusive as only 143 patients were included.

In the subgroup analyses, we found that the increased risks associated with blood type A were restricted to male patients. However, this was not unexpected. A case--control study in NPC ([@bib20]) observed a significantly higher rate of distant metastasis among male patients, but not female patients, with blood type A compared with non-A types (6.8% *vs* 3.5% *P*=0.027), which directly support the poorer prognostic value of blood type A in males. In addition, blood type A was associated with more advanced NPC in male patients, but not in female patients ([@bib20]); this suggests a lower survival rate in male patients with blood type A, despite the fact that no such association was observed in our study. Additionally, the recent study ([@bib13]) indicated that the female sex was positively associated with an early T-stage, N-stage, and clinical stage; reduced disease progression and cancer-related deaths, and was a favourable independent prognostic factor. In our study, female patients with blood type A had a higher proportion of early stage disease than those with non-A types had (38.6% *vs* 29.5% *P*=0.043). Therefore, the protective prognosis of female sex may confound the negative effects of blood type A on predicting survival of NPC, as we detected interactions (*P*=0.007) between gender and blood type (A/non-A). Second, blood type A was not associated with survival in patients with stage I and II disease. This may be explained by the fact that patients with early stage disease had relatively high rates of survival in general; therefore, it was difficult to observe significant survival differences according to a certain prognostic factor. Finally, as patients treated with RT alone mostly had early stage disease, it seems reasonable that no effects of blood group were observed in these patients. More importantly, small number of patients and low event rates in the female stratum, early stage stratum, and RT alone stratum are significant factors that cannot be ignored.

It is still not clear why ABO blood groups affect the survival of patients with NPC. As no significant differences in the basic characteristics of patients with blood type A and non-A types were observed, it is difficult to explain the effect of ABO blood groups based on this point. Underlying molecular and pathogenic differences may have more important roles in the effect of ABO blood groups on survival (see [Supplementary materials](#sup1){ref-type="supplementary-material"}).

In conclusion, this study provides the first evidence of association between ABO blood groups and survival in patients with NPC; patients with blood type A had poorer OS and DMFS than those with non-A types. Further basic researches into tumour genetic or biological differences associated with the ABO blood groups are required.
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###### Univariate and multivariate analyses of overall survival, locoregional relapse-free survival, and distant metastasis-free survival for the 924 patients with NPC in the intensity-modulated radiotherapy cohort

                                             **Blood group**   **Blood type A**                                                  
  ----------------------------------------- ----------------- ------------------- ------------------- ------------------- ------ -------------------
  **Overall survival**                                                                                                           
  No. of events                                    43                 43                  31                   8            82           43
  uHR (95% CI)                                    1.00         1.54 (1.01--2.35)   1.18 (0.74--1.87)   1.01 (0.47--2.15)   1.00   1.45 (1.00--2.10)
  *P*                                                                0.045               0.481               0.981                      0.048
  aHR (95% CI)[a](#t1-fn2){ref-type="fn"}         1.00         1.58 (1.03--2.43)   1.19 (0.75--1.90)   1.36 (0.63--2.92)   1.00   1.49 (1.03--2.17)
  *P*                                                                0.035               0.465               0.432                      0.036
  **Locoregional relapse-free survival**                                                                                         
  No. of events                                    24                 17                  16                   4            44           17
  uHR (95% CI)                                    1.00         1.10 (0.59--2.05)   1.13 (0.60--2.12)   1.00 (0.35--2.90)   1.00   1.06 (0.60--1.85)
  *P*                                                                0.756               0.709              00.994                      0.845
  aHR (95% CI)[a](#t1-fn2){ref-type="fn"}         1.00         1.16 (0.62--2.17)   1.14 (0.60--2.14)   1.14 (0.39--3.32)   1.00   1.10 (0.63--1.93)
  *P*                                                                0.638               0.694               0.806                      0.746
  **Distant metastasis-free survival**                                                                                           
  No. of events                                    43                 38                  22                   5            70           38
  uHR (95% CI)                                    1.00         1.38 (0.89--2.14)   0.84 (0.50--1.41)   0.65 (0.26--1.65)   1.00   1.52 (1.02--2.25)
  *P*                                                                0.146               0.511               0.369                      0.039
  aHR (95% CI)[a](#t1-fn2){ref-type="fn"}         1.00         1.62 (1.04--2.52)   0.90 (0.54--1.51)   0.93 (0.37--2.37)   1.00   1.68 (1.13--2.51)
  *P*                                                                0.033               0.685               0.882                      0.011

Abbreviations: aHR=adjusted hazard ratio; CI=confidence interval; NPC=nasopharyngeal carcinoma; uHR=unadjusted hazard ratio; VCA-IgA=immunoglobulin A against Epstein--Barr virus viral capsid antigen.

Adjusted for age group (⩽30, 31--40, 41--50, 51--60, and ⩾61 years-old), gender, smoking status at diagnosis (yes *vs* no), drinking status at diagnosis (yes *vs* no), T-stage (T1/T2/T3/T4), N-stage (N0/N1/N2/N3), titre of VCA-IgA (⩽1 : 160 *vs* \>1 : 160), and type of chemotherapy.

###### Univariate and multivariate analyses of overall survival, locoregional relapse-free survival, and distant metastasis-free survival in the 1193 patients with NPC in the conventional radiotherapy cohort

                                             **Blood group**   **Blood type A**                                                  
  ----------------------------------------- ----------------- ------------------- ------------------- ------------------- ------ -------------------
  **Overall survival**                                                                                                           
  No. of events                                    85                 79                  70                  14           169           79
  uHR (95% CI)                                    1.00         1.46 (1.07--1.98)   1.26 (0.92--1.74)   1.02 (0.58--1.79)   1.00   1.33 (1.02--1.73)
  *P*                                                                0.017               0.146               0.958                      0.038
  aHR (95% CI)[a](#t2-fn2){ref-type="fn"}         1.00         1.75 (1.24--2.47)   1.34 (0.94--1.91)   1.07 (0.58--1.99)   1.00   1.54 (1.15--2.07)
  *P*                                                                0.001               0.110               0.832                      0.004
  **Locoregional relapse-free survival**                                                                                         
  No. of events                                    53                 28                  23                  10            86           28
  uHR (95% CI)                                    1.00         0.81 (0.51--1.29)   0.66(0.40--1.07)    1.18 (0.60--2.32)   1.00   0.91 (0.60--1.40)
  *P*                                                                0.376               0.093               0.635                      0.672
  aHR (95% CI)[a](#t2-fn2){ref-type="fn"}         1.00         0.96 (0.56--1.64)   0.76 (0.44--1.33)   1.43 (0.69--2.97)   1.00   1.01(0.61--1.65)
  *P*                                                                0.876               0.340               0.338                      0.978
  **Distant metastasis-free survival**                                                                                           
  No. of events                                    50                 56                  43                   9           102           56
  uHR (95% CI)                                    1.00         1.73 (1.18--2.53)   1.32 (0.88--1.98)   1.10 (0.54--2.24)   1.00   1.54 (1.11--2.14)
  *P*                                                                0.005               0.188               0.790                      0.009
  aHR (95% CI)[a](#t2-fn2){ref-type="fn"}         1.00         1.77 (1.18--2.67)   1.24 (0.80--1.92)   1.15 (0.56--2.35)   1.00   1.61 (1.13--2.28)
  *P*                                                                0.006               0.332               0.712                      0.008

Abbreviations: aHR=adjusted hazard ratio; CI=confidence interval; NPC=nasopharyngeal carcinoma; uHR=unadjusted hazard ratio; VCA-IgA=immunoglobulin A against Epstein--Barr virus viral capsid antigen.

Adjusted for age group (⩽ 30, 31--40, 41--50, 51--60, and ⩾61 years-old), gender, smoking status at diagnosis (yes *vs* no), drinking status at diagnosis (yes *vs* no), T-stage (T1/T2/T3/T4), N-stage (N0/N1/N2/N3), titre of VCA-IgA (⩽1 : 160 *vs* \>1 : 160), and type of chemotherapy.

###### Subgroup analysis of OS by patient characteristics for the entire population of patients with NPC (*n*=2117)

                                                                  **No. of events/no. at risk**                                
  --------------------------------------------- ------ --------- ------------------------------- --------- ------------------- -------
  **Overall**                                    83.9                       247/1540              126/577   1.44 (1.16--1.78)   0.001
  **Age**                                               \<0.001                                                                    
   ⩽45 years-old                                 89.4                        79/758               50/308    1.65 (1.16--2.36)   0.006
   \>45 years-old                                78.3                        168/782              76/269    1.37 (1.04--1.80)   0.024
  **Gender**                                             0.002                                                                     
   Male                                          82.5                       200/1171              102/423   1.48 (1.16--1.88)   0.001
   Female                                        88.2                        47/369               24/154    1.18 (0.70--1.98)   0.531
  **Smoking status**                                    \<0.001                                                                    
   Yes                                           79.3                        148/703              73/261    1.36 (1.02--1.80)   0.036
   No                                            87.8                        99/837               53/316    1.55 (1.11--2.16)   0.011
  **Drinking status**                                   \<0.001                                                                    
   Yes                                           76.5                        40/204                35/90    2.18 (1.37--3.47)   0.001
   No                                            85.1                       207/1336              91/487    1.33 (1.01--1.76)   0.042
  **VCA-IgA**                                            0.038                                                                     
   ⩽1 : 160                                      85.7                        114/797              60/305    1.47 (1.07--2.02)   0.017
   \>1 : 160                                     81.9                        133/743              66/272    1.38 (1.03--1.86)   0.033
  **Clinical stage**                                    \<0.001                                                                    
   I+II                                          93.4                        33/447               16/185    1.56 (0.85--2.85)   0.150
   III+IV                                        79.7                       214/1093              110/392   1.50 (1.19--1.89)   0.001
  **Chemotherapy**[b](#t3-fn3){ref-type="fn"}           \<0.001                                                                    
   None                                          89.1                        49/346               15/130    0.74 (0.41--1.35)   0.332
   IC                                            70.6                        53/191                29/64    1.60 (1.01--2.53)   0.045
   CC                                            84.2                        85/561               47/232    1.60 (1.11--2.30)   0.011
   IC+CC                                         85.5                        45/342               29/126    1.64 (1.02--2.66)   0.043

Abbreviations: CC=concomitant chemotherapy; CI=confidence interval; HR=hazard ratio; IC=induction chemotherapy; NPC=nasopharyngeal carcinoma; OS=overall survival; VCA-IgA=immunoglobulin A against Epstein--Barr virus viral capsid antigen.

Adjusted for age group (⩽30, 31--40, 41--50, 51--60, and ⩾61 years-old), gender, smoking status at diagnosis (yes *vs* no), drinking status at diagnosis (yes *vs* no), T-stage (T1/T2/T3/T4), N-stage (N0/N1/N2/N3), titre of VCA-IgA (⩽1 : 160 *vs* \>1 : 160), radiation technique, and type of chemotherapy.

The subgroup of concomitant and adjuvant chemotherapy was excluded from analysis because of particular small number of patients (*n*=126).
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